Priority areas include CRC-specific promoters (CEA/CDX2), VEGF/EGFR-axis-informed combinations, and delivery routes tailored to disease anatomy (intratumoral, hepatic-arterial, systemic), each paired with standardized endpoints to enable cross-trial comparisons [131]. Here, VEGFA is linked to colorectal carcinoma.